Literature DB >> 19168445

Effect of androgen suppression compared with androgen receptor blockade on arterial stiffness in men with prostate cancer.

Frances Dockery1, Christopher J Bulpitt, Sanjiv Agarwal, Clare Vernon, Chakravarthi Rajkumar.   

Abstract

Endogenous testosterone and estradiol are thought to be cardio-protective in men. We wanted to determine the effects of 2 different anti-androgen therapies on arterial stiffness as one suppresses (goserelin--a gonadotrophin-releasing hormone analog) while the other increases (bicalutamide--an androgen receptor blocker) both testosterone and estradiol. We conducted a randomized trial on 43 men (mean age, 71.2 +/- 6.2 years) with localized prostate cancer. They received either goserelin or bicalutamide for 24 weeks. Carotid-femoral (C-F) and carotid-radial (C-R) pulse wave velocities (PWVs) were measured. Twenty age- and disease-matched men with prostate cancer on no active treatment were studied in a similar manner. After 12 weeks of goserelin, radial artery PWV increased significantly from baseline and a nonsignificant increase was observed in femoral PWV (change from baseline radial: +1.4 m/s, P = .002, femoral: +0.9 m/s, P = .127) Both PWV measures increased significantly with bicalutamide (change from baseline radial: +0.8, femoral: +0.9 m/s, P <or= .049). PWV increased further after 24 weeks with goserelin (change from baseline radial: +1.7, femoral: +1.3 m/s, P <or= .049 for both) but not bicalutamide (change from baseline radial: +0.4, femoral: +0.4 m/s, P not significant [NS]); however, comparison of changes between the 2 drugs were not significantly different at either 12 or 24 weeks (P >or= .967 at 12 weeks and P >or= .07 at 24 weeks). The untreated men studied in parallel showed no changes at 12 or 24 weeks in either PWV measure. Anti-androgen treatment in men might increase large artery stiffness, an adverse cardiovascular risk factor; however, the effect was not maintained with testosterone receptor blockade, in the longer term, but tended to be sustained with suppression therapy. This could relate to the different sex hormone effects of the 2 therapies.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19168445     DOI: 10.2164/jandrol.108.006924

Source DB:  PubMed          Journal:  J Androl        ISSN: 0196-3635


  8 in total

1.  Effect of androgen deprivation therapy on arterial stiffness and serum lipid profile changes in patients with prostate cancer: a prospective study of initial 6-month follow-up.

Authors:  Ryo Oka; Takanobu Utsumi; Takumi Endo; Masashi Yano; Shuichi Kamijima; Naoto Kamiya; Kohji Shirai; Hiroyoshi Suzuki
Journal:  Int J Clin Oncol       Date:  2015-08-22       Impact factor: 3.402

Review 2.  Cardiovascular Complications of Androgen Deprivation Therapy for Prostate Cancer.

Authors:  Dipti Gupta; Chadi Salmane; Susan Slovin; Richard M Steingart
Journal:  Curr Treat Options Cardiovasc Med       Date:  2017-08

Review 3.  Androgen deprivation therapy and cardiovascular disease: what is the linking mechanism?

Authors:  Piotr Zareba; Wilhelmina Duivenvoorden; Darryl P Leong; Jehonathan H Pinthus
Journal:  Ther Adv Urol       Date:  2015-11-30

Review 4.  Testosterone replacement therapy and cardiovascular risk.

Authors:  Thiago Gagliano-Jucá; Shehzad Basaria
Journal:  Nat Rev Cardiol       Date:  2019-09       Impact factor: 32.419

Review 5.  Androgen actions on endothelium functions and cardiovascular diseases.

Authors:  Jing-Jing Cai; Juan Wen; Wei-Hong Jiang; Jian Lin; Yuan Hong; Yuan-Shan Zhu
Journal:  J Geriatr Cardiol       Date:  2016-02       Impact factor: 3.327

Review 6.  Cardiovascular Toxicities of Androgen Deprivation Therapy.

Authors:  Azariyas A Challa; Adam Christopher Calaway; Jennifer Cullen; Jorge Garcia; Nihar Desai; Neal L Weintraub; Anita Deswal; Shelby Kutty; Ajay Vallakati; Daniel Addison; Ragavendra Baliga; Courtney M Campbell; Avirup Guha
Journal:  Curr Treat Options Oncol       Date:  2021-04-17

7.  The SIAMS-ED Trial: A National, Independent, Multicentre Study on Cardiometabolic and Hormonal Impairment of Men with Erectile Dysfunction Treated with Vardenafil.

Authors:  Andrea M Isidori; Giovanni Corona; Antonio Aversa; Daniele Gianfrilli; Emmanuele A Jannini; Carlo Foresta; Mario Maggi; Andrea Lenzi
Journal:  Int J Endocrinol       Date:  2014-05-15       Impact factor: 3.257

8.  Effect of androgen deprivation therapy on cardiovascular function in Chinese patients with advanced prostate cancer: a prospective cohort study.

Authors:  Chi-Fai Ng; Peter K F Chiu; Chi-Hang Yee; Becky S Y Lau; Steven C H Leung; Jeremy Y C Teoh
Journal:  Sci Rep       Date:  2020-10-22       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.